Added to YB: 2026-01-07
Pitch date: 2026-01-04
ZTS [neutral]
Zoetis Inc.
+0.02%
current return
Author Info
Rebound Capital shares deep research on beaten-down stocks. Sign up for the newsletter.
Company Info
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally.
Market Cap
$57.0B
Pitch Price
$125.64
Price Target
N/A
Dividend
1.64%
EV/EBITDA
15.24
P/E
21.79
EV/Sales
6.62
Sector
Pharmaceuticals
Category
N/A
Built to Last: 10 Resilient Rebounds for 2026 - Zoetis Inc.
ZTS (pass): Leader in animal health w/ $9.5B 2025 revenue projection. Stock down 13% Nov 4th on lowered guidance due to blockbuster osteoarthritis drug Librela facing adverse neurological effect allegations via social media & class action suits. Strong innovation pipeline & pet humanization trend support long-term model, but serious liability concerns warrant waiting several quarters.
Read full article (2 min)